Literature DB >> 26072633

Histologic classification of prostate cancer.

Gregor Mikuz.   

Abstract

Apart from the typical acinar morphology observed in more than 90% of prostatic adenocarcinomas, a spectrum of morphological variants and prostate cancer subtypes exists. Two nosologically different groups can be distinguished: the variants of conventional acinar cancer and cancers with histological pattern, which are unusual for the prostate. Variants of conventional prostate cancer (pseudohyperplastic, foamy gland, hypernephroid, atrophic, microcystic, with Paneth cell-like changes, with collagenous micronodules, with glomeruloid formations, oncocytic) do not have any known prognostic significance and are graded according to the Gleason system. Unusual cancer types (ductal carcinoma, mucinous [colloid] carcinoma, mucinous signet ring cell carcinoma, small cell carcinoma, sarcomatoid carcinoma and carcinosarcoma, pleomorphic giant cell carcinoma, squamous and adenosquamous carcinoma, basal cell and adenoid cystic carcinoma, lymphoepithelioma-like carcinoma, primary urothelial carcinoma of the prostate) have mostly a very poor prognosis and are therefore real nosological entities.

Entities:  

Mesh:

Year:  2015        PMID: 26072633

Source DB:  PubMed          Journal:  Anal Quant Cytopathol Histpathol        ISSN: 2578-742X


  3 in total

1.  Prostatic adenocarcinoma oncocytic variant: Case report and literature review.

Authors:  Matthew M Klairmont; Nadeem Zafar
Journal:  World J Clin Oncol       Date:  2017-06-10

Review 2.  The benign mimickers of prostatic acinar adenocarcinoma.

Authors:  Yuqiao Xu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Zhe Wang; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  The effects of histone crotonylation and bromodomain protein 4 on prostate cancer cell lines.

Authors:  Xiaolin Xu; Xin Zhu; Feng Liu; Wenlong Lu; Yihan Wang; Jianjun Yu
Journal:  Transl Androl Urol       Date:  2021-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.